The San Francisco-based biotechnology firm is set to detail its latest fiscal performance as it continues development of its core pipeline, including the lead candidate rezpegaldesleukin. Interested parties can access the live audio webcast via the company’s investor relations portal. Participants wishing to join the conference call by phone must pre-register to receive specific dial-in credentials and an access PIN. The recording of the session will remain available for playback on the company website through September 13, 2026.

Nektar remains focused on clinical-stage research targeting immunological dysfunction, specifically in autoimmune and chronic inflammatory conditions. Beyond the ongoing registrational programs for atopic dermatitis and alopecia areata, the company is evaluating rezpegaldesleukin in a Phase 2 trial for Type 1 diabetes mellitus. The broader research portfolio includes early-stage programs such as the TNFR2 antibody candidates NKTR-0165 and NKTR-0166, alongside the protein treatment NKTR-422.